Sign up USA
Proactive Investors - Run By Investors For Investors

Catabasis Pharmaceuticals reports positive pre-clinical data for DMD treatment

Dr H Lee Sweeney, who led the research, said: "There remains a large unmet need in Duchenne for therapies that can treat all affected boys and slow disease progression.
Catabasis Pharmaceuticals reports positive pre-clinical data for DMD treatment
The firm reported on pre-clinical data today

Shares in Catabasis Pharmaceuticals Inc (NASDAQ:CATB) advanced as it reported positive pre-clinical data for the treatment of muscle-wasting disease Duchenne muscular dystrophy (DMD).

The data comes from the edasalonexent programme, which showed two inhibitors edasalonexent (CAT-1004) and CAT-1041 are effective in making better the dystrophic process in two animal models.

Dr H Lee Sweeney, who led the research, said: "There remains a large unmet need in Duchenne for therapies that can treat all affected boys and slow disease progression.

"The orally bioavailable NF-kB inhibitors, edasalonexent and CAT-1041, improve the severe dystrophic phenotype found in both mechanically-damaged mdx mice and a GRMD dog and create an environment that can support more successful muscle regeneration."

Catabasis's chief scientific officer Dr Andrew Nichols, added: "We very much appreciate the research performed by Dr Sweeney and his colleagues.

"We agree that these data support edasalonexent as a potential treatment to improve both the quantity and quality of muscle fibers in boys affected by DMD and look forward to the Phase 2 clinical trial results with edasalonexent in the first half of Q1 2017."

Another DMD firm -  Summit Therapeutics (LON:SUMM) is in a phase II trial with its potentially breakthrough treatment for the disease.

In October, it inked a licensing deal with US biotech Sarepta Therapeutics (NASDAQ:SRPT) worth up to US$522mln.

Shares added 2.49% to US$3.70.

Giles_55af4ddca6481.jpg


Register here to be notified of future CATB Company articles
View full CATB profile

Catabasis Pharma Timeline

Related Articles

Medical test
August 10 2016
The STOP-HCV-1 clinical trial will assess two direct acting anti-viral (DAA) treatment combinations and whether the addition of another, older drug has value in short course treatment
a child with asthma using an inhaler
September 22 2016
Phase II results for its prospective asthma treatment are due next year, while its LOXL2 collaboration with Pharmaxis is set for a Phase I trial in 2017
Concept of a DNA strand
February 14 2017
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making advances altering the inner workings of the human body to tackle deadly diseases
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use